Tower Research Capital LLC (TRC) - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 2 filers reported holding BRIDGEBIO PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$52,370
-78.5%
1,986
-86.0%
0.00%
-75.0%
Q2 2023$243,534
+338141.7%
14,159
+222.7%
0.01%
+300.0%
Q1 2023$72
+44.0%
4,388
-32.3%
0.00%0.0%
Q4 2022$50
-100.0%
6,484
-61.4%
0.00%
-33.3%
Q3 2022$167,000
-44.0%
16,795
-48.8%
0.00%
-57.1%
Q2 2022$298,000
+66.5%
32,813
+86.8%
0.01%
+250.0%
Q1 2022$179,000
-34.9%
17,566
+6.4%
0.00%
-60.0%
Q4 2021$275,000
-50.4%
16,516
+39.6%
0.01%
-64.3%
Q3 2021$554,000
+69.9%
11,832
+121.3%
0.01%
+75.0%
Q2 2021$326,000
-30.2%
5,347
-29.4%
0.01%0.0%
Q1 2021$467,000
+165.3%
7,579
+206.3%
0.01%
+60.0%
Q4 2020$176,000
+38.6%
2,474
-26.6%
0.01%
+400.0%
Q3 2020$127,000
-83.6%
3,371
-85.8%
0.00%
-96.9%
Q2 2020$775,000
+1939.5%
23,776
+2067.4%
0.03%
+966.7%
Q4 2019$38,000
+280.0%
1,097
+136.9%
0.00%
+200.0%
Q3 2019$10,0004630.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2023
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders